Co-amoxiclav 1000mg/200mg powder for solution for injection vials
NHS hospitals in England used £24,708,733 of indicative cost of Co-amoxiclav 1000mg/200mg powder for solution for injection vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 9.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Co-amoxiclav 1000mg/200mg powder for solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Co-amoxiclav 1000mg/200mg powder for solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Southend Univ Hosp Nhs Foundation Trust | £1,074,086 |
| University Hpls Of Leicester Nhs Trust | £779,043 |
| Barts Health Nhs Trust | £752,478 |
| Univ Hpl B/Ham Nhs Foundation Trust | £734,231 |
| Royal Free London Nhs Foundation Trust | £656,382 |
| East Kent Hospitals University Nhs Ft | £586,097 |
| Western Sussex Hospitals Nhs Found Trust | £505,587 |
| London North West Healthcare Nhs Trust | £492,022 |
| Manchester University Nhs Ft | £474,026 |
| Colchester Hospital University Nhs Ft | £469,739 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.